234 related articles for article (PubMed ID: 28637689)
1. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
Yang WL; Gentry-Maharaj A; Simmons A; Ryan A; Fourkala EO; Lu Z; Baggerly KA; Zhao Y; Lu KH; Bowtell D; Jacobs I; Skates SJ; He WW; Menon U; Bast RC;
Clin Cancer Res; 2017 Oct; 23(19):5912-5922. PubMed ID: 28637689
[No Abstract] [Full Text] [Related]
2. Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population.
Blyuss O; Burnell M; Ryan A; Gentry-Maharaj A; Mariño IP; Kalsi J; Manchanda R; Timms JF; Parmar M; Skates SJ; Jacobs I; Zaikin A; Menon U
Clin Cancer Res; 2018 Oct; 24(19):4726-4733. PubMed ID: 30084833
[No Abstract] [Full Text] [Related]
3. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
[TBL] [Abstract][Full Text] [Related]
4. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH
Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870
[No Abstract] [Full Text] [Related]
5. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.
Wu J; Yin H; Zhu J; Buckanovich RJ; Thorpe JD; Dai J; Urban N; Lubman DM
PLoS One; 2015; 10(3):e0121112. PubMed ID: 25799488
[TBL] [Abstract][Full Text] [Related]
6. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
Rosenthal AN; Fraser LSM; Philpott S; Manchanda R; Burnell M; Badman P; Hadwin R; Rizzuto I; Benjamin E; Singh N; Evans DG; Eccles DM; Ryan A; Liston R; Dawnay A; Ford J; Gunu R; Mackay J; Skates SJ; Menon U; Jacobs IJ;
J Clin Oncol; 2017 May; 35(13):1411-1420. PubMed ID: 28240969
[TBL] [Abstract][Full Text] [Related]
7. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
[TBL] [Abstract][Full Text] [Related]
8. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
Fujiwara H; Suzuki M; Takeshima N; Takizawa K; Kimura E; Nakanishi T; Yamada K; Takano H; Sasaki H; Koyama K; Ochiai K
Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
[TBL] [Abstract][Full Text] [Related]
10. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC
Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
[TBL] [Abstract][Full Text] [Related]
12. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.
Menon U; Ryan A; Kalsi J; Gentry-Maharaj A; Dawnay A; Habib M; Apostolidou S; Singh N; Benjamin E; Burnell M; Davies S; Sharma A; Gunu R; Godfrey K; Lopes A; Oram D; Herod J; Williamson K; Seif MW; Jenkins H; Mould T; Woolas R; Murdoch JB; Dobbs S; Amso NN; Leeson S; Cruickshank D; Scott I; Fallowfield L; Widschwendter M; Reynolds K; McGuire A; Campbell S; Parmar M; Skates SJ; Jacobs I
J Clin Oncol; 2015 Jun; 33(18):2062-71. PubMed ID: 25964255
[TBL] [Abstract][Full Text] [Related]
13. p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer.
Häfner N; Nicolaus K; Weiss S; Frey M; Diebolder H; Rengsberger M; Dürst M; Runnebaum IB
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1207-10. PubMed ID: 23576021
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials.
Skates SJ
Int J Gynecol Cancer; 2012 May; 22 Suppl 1(Suppl 1):S24-6. PubMed ID: 22543916
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
16. Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence.
Chatterjee M; Dyson G; Levin NK; Shah JP; Morris R; Munkarah A; Tainsky MA
Cancer Biomark; 2012; 11(2-3):59-73. PubMed ID: 23011153
[TBL] [Abstract][Full Text] [Related]
17. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
[TBL] [Abstract][Full Text] [Related]
18. Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
Lentz SE; Powell CB; Haque R; Armstrong MA; Anderson M; Liu Y; Jiang W; Chillemi G; Shaw S; Alvarado MM; Kushi LH; Skates SJ
Gynecol Oncol; 2020 Dec; 159(3):804-810. PubMed ID: 33012551
[TBL] [Abstract][Full Text] [Related]
19. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC
Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597
[TBL] [Abstract][Full Text] [Related]
20. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.
Pinsky PF; Zhu C; Skates SJ; Black A; Partridge E; Buys SS; Berg CD
Int J Cancer; 2013 May; 132(9):2127-33. PubMed ID: 23065684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
